Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 104

Similar articles for PubMed (Select 15924335)

1.

Heparin affin regulatory peptide is a key player in prostate cancer cell growth and angiogenicity.

Hatziapostolou M, Delbe J, Katsoris P, Polytarchou C, Courty J, Papadimitriou E.

Prostate. 2005 Oct 1;65(2):151-8.

PMID:
15924335
2.

Proliferation and migration activities of fibroblast growth factor-2 in endothelial cells are modulated by its direct interaction with heparin affin regulatory peptide.

Dos Santos C, Blanc C, Elahouel R, Prescott M, Carpentier G, Ori A, Courty J, Hamma-Kourbali Y, Fernig DG, Delbé J.

Biochimie. 2014 Dec;107 Pt B:350-7. doi: 10.1016/j.biochi.2014.10.002. Epub 2014 Oct 12.

PMID:
25315978
3.

Classical? Celtic harp? Big band? Show tunes? What turns you on in the or?

Lagay F, Taub S.

Virtual Mentor. 2001 Jan 1;3(1). pii: virtualmentor.2001.3.1.ebyt1-0101. doi: 10.1001/virtualmentor.2001.3.1.ebyt1-0101. No abstract available.

4.

The synthetic peptide P111-136 derived from the C-terminal domain of heparin affin regulatory peptide inhibits tumour growth of prostate cancer PC-3 cells.

Hamma-Kourbali Y, Bermek O, Bernard-Pierrot I, Karaky R, Martel-Renoir D, Frechault S, Courty J, Delbé J.

BMC Cancer. 2011 May 30;11:212. doi: 10.1186/1471-2407-11-212.

5.

An old player on a new playground: bmi-1 as a regulator of prostate stem cells.

Laffin B, Tang DG.

Cell Stem Cell. 2010 Dec 3;7(6):639-40. doi: 10.1016/j.stem.2010.11.019. No abstract available.

6.

A Pleiotrophin C-terminus peptide induces anti-cancer effects through RPTPβ/ζ.

Diamantopoulou Z, Bermek O, Polykratis A, Hamma-Kourbali Y, Delbé J, Courty J, Katsoris P.

Mol Cancer. 2010 Aug 25;9:224. doi: 10.1186/1476-4598-9-224.

7.

The Hospital Admission Risk Profile (HARP).

Graf C.

Medsurg Nurs. 2010 Mar-Apr;19(2):133-4. No abstract available.

PMID:
20496501
8.

Antitumorigenic effects of a mutant of the heparin affin regulatory peptide on the U87 MG glioblastoma cell line.

Dos Santos C, Karaky R, Renoir D, Hamma-Kourbali Y, Albanese P, Gobbo E, Griscelli F, Opolon P, Dalle S, Perricaudet M, Courty J, Delbé J.

Int J Cancer. 2010 Sep 1;127(5):1038-51. doi: 10.1002/ijc.25110.

PMID:
20013808
9.

Annexin-A7 protects normal prostate cells and induces distinct patterns of RB-associated cytotoxicity in androgen-sensitive and -resistant prostate cancer cells.

Torosyan Y, Simakova O, Naga S, Mezhevaya K, Leighton X, Diaz J, Huang W, Pollard H, Srivastava M.

Int J Cancer. 2009 Dec 1;125(11):2528-39. doi: 10.1002/ijc.24592.

PMID:
19610065
10.

Novel mechanism of IGF-binding protein-3 action on prostate cancer cells: inhibition of proliferation, adhesion, and motility.

Massoner P, Colleselli D, Matscheski A, Pircher H, Geley S, Jansen Dürr P, Klocker H.

Endocr Relat Cancer. 2009 Sep;16(3):795-808. doi: 10.1677/ERC-08-0175. Epub 2009 Jun 9.

11.

Tranilast inhibits hormone refractory prostate cancer cell proliferation and suppresses transforming growth factor beta1-associated osteoblastic changes.

Izumi K, Mizokami A, Li YQ, Narimoto K, Sugimoto K, Kadono Y, Kitagawa Y, Konaka H, Koh E, Keller ET, Namiki M.

Prostate. 2009 Aug 1;69(11):1222-34. doi: 10.1002/pros.20975.

PMID:
19434660
12.

Ubiquitous mitochondrial creatine kinase is overexpressed in the conditioned medium and the extract of LNCaP lineaged androgen independent cell lines and facilitates prostate cancer progression.

Pang B, Zhang H, Wang J, Chen WZ, Li SH, Shi QG, Liang RX, Xie BX, Wu RQ, Qian XL, Yu L, Li QM, Huang CF, Zhou JG.

Prostate. 2009 Aug 1;69(11):1176-87. doi: 10.1002/pros.20969.

PMID:
19415690
13.

The prostatic environment suppresses growth of androgen-independent prostate cancer xenografts: an effect influenced by testosterone.

Jennbacken K, Gustavsson H, Tesan T, Horn M, Vallbo C, Welén K, Damber JE.

Prostate. 2009 Aug 1;69(11):1164-75. doi: 10.1002/pros.20965.

PMID:
19399749
14.

Bone morphogenetic protein-10 suppresses the growth and aggressiveness of prostate cancer cells through a Smad independent pathway.

Ye L, Kynaston H, Jiang WG.

J Urol. 2009 Jun;181(6):2749-59. doi: 10.1016/j.juro.2009.01.098. Epub 2009 Apr 17.

PMID:
19375725
15.

The Hospital Admission Risk Profile (HARP).

Graf C.

Medsurg Nurs. 2008 Dec;17(6):437-8. No abstract available.

PMID:
19248413
16.

Fascin regulates prostate cancer cell invasion and is associated with metastasis and biochemical failure in prostate cancer.

Darnel AD, Behmoaram E, Vollmer RT, Corcos J, Bijian K, Sircar K, Su J, Jiao J, Alaoui-Jamali MA, Bismar TA.

Clin Cancer Res. 2009 Feb 15;15(4):1376-83. doi: 10.1158/1078-0432.CCR-08-1789.

17.

Vasoactive intestinal peptide behaves as a pro-metastatic factor in human prostate cancer cells.

Fernández-Martínez AB, Bajo AM, Sánchez-Chapado M, Prieto JC, Carmena MJ.

Prostate. 2009 May 15;69(7):774-86. doi: 10.1002/pros.20930.

PMID:
19189304
18.

Extratumoral macrophages promote tumor and vascular growth in an orthotopic rat prostate tumor model.

Halin S, Rudolfsson SH, Van Rooijen N, Bergh A.

Neoplasia. 2009 Feb;11(2):177-86.

19.

Piperazine-designed alpha 1A/alpha 1D-adrenoceptor blocker KMUP-1 and doxazosin provide down-regulation of androgen receptor and PSA in prostatic LNCaP cells growth and specifically in xenografts.

Liu CM, Lo YC, Tai MH, Wu BN, Wu WJ, Chou YH, Chai CY, Huang CH, Chen IJ.

Prostate. 2009 May 1;69(6):610-23. doi: 10.1002/pros.20919.

PMID:
19143029
20.

Regulatory effects of ferritin on angiogenesis.

Coffman LG, Parsonage D, D'Agostino R Jr, Torti FM, Torti SV.

Proc Natl Acad Sci U S A. 2009 Jan 13;106(2):570-5. doi: 10.1073/pnas.0812010106. Epub 2009 Jan 6.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk